22:11 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Gastric cancer Patient sample, cell culture and mouse studies suggest inhibiting IRF3 could help treat gastric cancer. In patient samples, high levels of IRF3 tumor RNA and protein correlated with tumor size and poor...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Company News

Medigene, Cowen Healthcare Royalty Partners L.P. deal

MediGene sold Cowen Healthcare Royalty Partners a 2% royalty on European sales of Eligard leuprolide for $17.7 million in cash. The royalty comes from MediGene's 2010 deal that gave Astellas Pharma Inc. (Tokyo:4503, Tokyo, Japan)...
08:00 , Feb 14, 2011 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals, Allergan sales and marketing update

Allergen granted Valeant's Biovail Laboratories International SRL subsidiary exclusive Canadian rights to Aczone dapsone topical gel 5% to treat acne vulgaris. Allergan will receive C$500,000 ($506,050) up front and is eligible for sales-based milestones. The...
08:00 , Jan 24, 2011 |  BC Week In Review  |  Company News

Astellas, Tolmar sales and marketing update

Tolmar granted Astellas' Astellas Pharma Europe Ltd. subsidiary marketing rights to Eligard leuprolide acetate in China, Taiwan, Thailand, Hong Kong, the Philippines, Indonesia, the Middle East, North Africa and Commonwealth of Independent States to treat...
07:00 , Jul 26, 2010 |  BC Week In Review  |  Company News

MediGene, Astellas sales and marketing update

MediGene sold partner Astellas full European marketing rights to Eligard leuprolide for €25 million ($32.3 million). MediGene also is eligible for single-digit royalties. MediGene had European rights to the prostate cancer drug under a 2001...
07:00 , Sep 10, 2007 |  BC Week In Review  |  Clinical News

Eligard leuprolide acetate regulatory update

QLT said a 6-month formulation of Eligard leuprolide 45 mg has been approved to treat advanced prostate cancer in the EU under the European Mutual Recognition Procedure. Germany acted as a reference member state after...
07:00 , May 28, 2007 |  BC Week In Review  |  Company News

Zila board of directors update

Zila Inc. (ZILA), Phoenix, Ariz.   Business: Dental, Diagnostic   Appointed: David Bethune, former chairman and CEO of Atrix Laboratories Inc. , as chairman; he replaces Douglas Burkett, who will remain president, CEO and a...
08:00 , Feb 12, 2007 |  BC Week In Review  |  Company News

QLT, sanofi-aventis, Takeda, Tap Holdings, Wako Pure Chemical cancer news

QLT said it and partner SAN will pay $112.5 million and $45 million, respectively, to settle a patent infringement lawsuit related to prostate cancer drug Eligard leuprolide acetate. In 2003, Takeda, Tap and Wako filed...
02:09 , Feb 10, 2007 |  BC Extra  |  Company News

QLT, sanofi-aventis settle Eligard lawsuit

QLT (TSX:QLT; QLTI) said it and partner sanofi-aventis (Euronext:SAN; SNY) will pay $112.5 million and $45 million, respectively, to settle a patent infringement lawsuit related to prostate cancer drug Eligard leuprolide acetate. In 2003, Takeda...
08:00 , Dec 11, 2006 |  BC Week In Review  |  Clinical News

Eligard leuprolide acetate regulatory update

The partners received marketing approval in Germany for a 6-month formulation of 45 mg Eligard to treat advanced prostate cancer. Approval in other EU countries is expected through mutual recognition procedure with Germany acting as...